Watson Wins EU Approval to Buy Generic-Drug Maker Actavis

Watson Pharmaceuticals Inc. (WPI), maker of the generic version of Lipitor cholesterol pills, won European Union approval to buy closely held drugmaker Actavis Group hf to create the third-largest global generic-drug maker.

The European Commission said the combined company would continue to face competition from a sufficient number of credible and strong rivals, according to an e-mailed statement today.

Parsippany, New Jersey-based Watson agreed in April to buy Actavis for 4.25 billion euros ($5.6 billion), expanding its reach in Europe and Asia.

To contact the reporter on this story: Aoife White in Brussels at awhite62@bloomberg.net.

To contact the editor responsible for this story: Anthony Aarons at aaarons@bloomberg.net.

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.